Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GSK 2618960

Drug Profile

GSK 2618960

Alternative Names: GSK-2618960

Latest Information Update: 28 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Class Monoclonal antibodies
  • Mechanism of Action Interleukin 7 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Sjogren's syndrome
  • Discontinued Multiple sclerosis

Most Recent Events

  • 28 Apr 2019 No recent reports of development identified for phase-I development in Sjogren's-syndrome in United Kingdom (IV, Injection)
  • 24 Jun 2018 Biomarkers information updated
  • 13 Nov 2017 GlaxoSmithKline withdraws a phase II trial in Sjogren's syndrome (In the elderly, In adults) in United Kingdom for portfolio prioritisation (IV) (EudraCT2016-004258-14) (NCT03239600)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top